Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression

Songtao Shi, Stan Gronthos, Shaoqiong Chen, Anand Reddi, Christopher M. Counter, Pamela G. Robey, Cun Yu Wang

Research output: Contribution to journalArticle

295 Citations (Scopus)

Abstract

Human postnatal bone marrow stromal stem cells (BMSSCs) have a limited life-span and progressively lose their stem cell properties during ex vivo expansion. Here we report that ectopic expression of human telomerase reverse transcriptase (hTERT) in BMSSCs extended their life-span and maintained their osteogenic potential. In xenogenic transplants, hTERT-expressing BMSSCs (BMSSC-Ts) generated more bone tissue, with a mineralized lamellar bone structure and associated marrow, than did control BMSSCs. The enhanced bone-forming ability of BMSSC-Ts was correlated with a higher and sustained expression of the early preosteogenic stem cell marker STRO-1, indicating that telomerase expression helped to maintain the osteogenic stem cell pool during ex viva expansion. These results show that telomerase expression can overcome critical technical barriers to the ex vivo expansion of BMSSCs, and suggest that telomerase therapy may be a useful strategy for bone regeneration and repair.

LanguageEnglish
Pages587-591
Number of pages5
JournalNature Biotechnology
Volume20
Issue number6
DOIs
Publication statusPublished - 1 Jan 2002

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Molecular Medicine
  • Biomedical Engineering

Cite this

Shi, Songtao ; Gronthos, Stan ; Chen, Shaoqiong ; Reddi, Anand ; Counter, Christopher M. ; Robey, Pamela G. ; Wang, Cun Yu. / Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. In: Nature Biotechnology. 2002 ; Vol. 20, No. 6. pp. 587-591.
@article{22f80635f71e45bc8e9cd9cc4a3da584,
title = "Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression",
abstract = "Human postnatal bone marrow stromal stem cells (BMSSCs) have a limited life-span and progressively lose their stem cell properties during ex vivo expansion. Here we report that ectopic expression of human telomerase reverse transcriptase (hTERT) in BMSSCs extended their life-span and maintained their osteogenic potential. In xenogenic transplants, hTERT-expressing BMSSCs (BMSSC-Ts) generated more bone tissue, with a mineralized lamellar bone structure and associated marrow, than did control BMSSCs. The enhanced bone-forming ability of BMSSC-Ts was correlated with a higher and sustained expression of the early preosteogenic stem cell marker STRO-1, indicating that telomerase expression helped to maintain the osteogenic stem cell pool during ex viva expansion. These results show that telomerase expression can overcome critical technical barriers to the ex vivo expansion of BMSSCs, and suggest that telomerase therapy may be a useful strategy for bone regeneration and repair.",
author = "Songtao Shi and Stan Gronthos and Shaoqiong Chen and Anand Reddi and Counter, {Christopher M.} and Robey, {Pamela G.} and Wang, {Cun Yu}",
year = "2002",
month = "1",
day = "1",
doi = "10.1038/nbt0602-587",
language = "English",
volume = "20",
pages = "587--591",
journal = "Nature Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "6",

}

Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. / Shi, Songtao; Gronthos, Stan; Chen, Shaoqiong; Reddi, Anand; Counter, Christopher M.; Robey, Pamela G.; Wang, Cun Yu.

In: Nature Biotechnology, Vol. 20, No. 6, 01.01.2002, p. 587-591.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression

AU - Shi, Songtao

AU - Gronthos, Stan

AU - Chen, Shaoqiong

AU - Reddi, Anand

AU - Counter, Christopher M.

AU - Robey, Pamela G.

AU - Wang, Cun Yu

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Human postnatal bone marrow stromal stem cells (BMSSCs) have a limited life-span and progressively lose their stem cell properties during ex vivo expansion. Here we report that ectopic expression of human telomerase reverse transcriptase (hTERT) in BMSSCs extended their life-span and maintained their osteogenic potential. In xenogenic transplants, hTERT-expressing BMSSCs (BMSSC-Ts) generated more bone tissue, with a mineralized lamellar bone structure and associated marrow, than did control BMSSCs. The enhanced bone-forming ability of BMSSC-Ts was correlated with a higher and sustained expression of the early preosteogenic stem cell marker STRO-1, indicating that telomerase expression helped to maintain the osteogenic stem cell pool during ex viva expansion. These results show that telomerase expression can overcome critical technical barriers to the ex vivo expansion of BMSSCs, and suggest that telomerase therapy may be a useful strategy for bone regeneration and repair.

AB - Human postnatal bone marrow stromal stem cells (BMSSCs) have a limited life-span and progressively lose their stem cell properties during ex vivo expansion. Here we report that ectopic expression of human telomerase reverse transcriptase (hTERT) in BMSSCs extended their life-span and maintained their osteogenic potential. In xenogenic transplants, hTERT-expressing BMSSCs (BMSSC-Ts) generated more bone tissue, with a mineralized lamellar bone structure and associated marrow, than did control BMSSCs. The enhanced bone-forming ability of BMSSC-Ts was correlated with a higher and sustained expression of the early preosteogenic stem cell marker STRO-1, indicating that telomerase expression helped to maintain the osteogenic stem cell pool during ex viva expansion. These results show that telomerase expression can overcome critical technical barriers to the ex vivo expansion of BMSSCs, and suggest that telomerase therapy may be a useful strategy for bone regeneration and repair.

UR - http://www.scopus.com/inward/record.url?scp=0035984715&partnerID=8YFLogxK

U2 - 10.1038/nbt0602-587

DO - 10.1038/nbt0602-587

M3 - Article

VL - 20

SP - 587

EP - 591

JO - Nature Biotechnology

T2 - Nature Biotechnology

JF - Nature Biotechnology

SN - 1087-0156

IS - 6

ER -